SC
GILD icon

Stance Capital’s Gilead Sciences GILD Stock Holding History

Stance Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.56M Buy
36,089
+26,548
+278% +$3.5M 1.39% 11
2026
Q1 		$1.33M Sell
9,541
-1,731
-15% -$242K 0.65% 67
2025
Q4 		$1.38M Sell
11,272
-817
-7% -$99.3K 0.51% 82
2025
Q3 		$1.34M Buy
12,089
+264
+2% +$30K 0.49% 93
2025
Q2 		$1.31M Buy
+11,825
New +$1.26M 0.49% 111
2025
Q1 		– Sell
-8
Closed -$739 – 141
2024
Q4 		$739 Buy
+8
New +$720 ﹤0.01% 234

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stance Capital's GILD Position: Q2 2026 in Review

Stance Capital increased its Gilead Sciences (GILD) stake by 278% in Q2 2026, buying an estimated $3.5M and bringing the position to 36,089 shares worth $4.56M. The position accounts for 1.39% of the portfolio, ranked #11.

Stance Capital first reported a position in GILD in Q4 2024 and has held it in 6 quarters since. 2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Stance Capital held 36,089 shares of Gilead Sciences worth $4.56M as of Q2 2026.
  • Stance Capital bought 26,548 Gilead Sciences shares in Q2 2026, an estimated $3.5M.
  • Gilead Sciences made up 1.39% of Stance Capital's portfolio in Q2 2026, its #11 holding.
  • Stance Capital first reported a position in Gilead Sciences in Q4 2024 and has held it in 6 quarters since.
  • 2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.